Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.95)
# 4,192
Out of 4,966 analysts
141
Total ratings
54.93%
Success rate
39.19%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $10.59 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $22.03 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $580.70 | +46.38% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $1.17 | +1,438.46% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $1.68 | +3,471.43% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $2.59 | +247.49% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $9.25 | +267.57% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $132.22 | +147.32% | 7 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $3.08 | +874.03% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $408 → $568 | $11.38 | +4,891.21% | 2 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $391.02 | -28.14% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $3.14 | +154.78% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.04 | +9,323.08% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $287.71 | +2.53% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $112.97 | -23.87% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $29.33 | +63.65% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $7.38 | +306.50% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $37.71 | +90.93% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.31 | +281.68% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $84.61 | +18.19% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $194.27 | +3.46% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $49.33 | +72.31% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $11.99 | +166.89% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $18.20 | +1,092.31% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $20.33 | +136.10% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $13.83 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $446.51 | -65.51% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $58.27 | +99.07% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $5.02 | +2,011.55% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $11.36 | +146.59% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $206.94 | -60.37% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $304.76 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.04 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.59
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.03
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $580.70
Upside: +46.38%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $1.17
Upside: +1,438.46%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $1.68
Upside: +3,471.43%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $2.59
Upside: +247.49%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $9.25
Upside: +267.57%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $132.22
Upside: +147.32%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $3.08
Upside: +874.03%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $408 → $568
Current: $11.38
Upside: +4,891.21%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $391.02
Upside: -28.14%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $3.14
Upside: +154.78%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.04
Upside: +9,323.08%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $287.71
Upside: +2.53%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $112.97
Upside: -23.87%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $29.33
Upside: +63.65%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $7.38
Upside: +306.50%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $37.71
Upside: +90.93%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.31
Upside: +281.68%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $84.61
Upside: +18.19%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $194.27
Upside: +3.46%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $49.33
Upside: +72.31%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $11.99
Upside: +166.89%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $18.20
Upside: +1,092.31%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $20.33
Upside: +136.10%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $13.83
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $446.51
Upside: -65.51%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $58.27
Upside: +99.07%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $5.02
Upside: +2,011.55%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $11.36
Upside: +146.59%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $206.94
Upside: -60.37%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $304.76
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $2.04
Upside: -